Mizuho lowered the firm’s price target on Insmed (INSM) to $204 from $211 and keeps an Outperform rating on the shares post the Q4 report. The company offered “highly positive comments” on the Brinsupri launch, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed price target raised to $166 from $162 at Morgan Stanley
- Insmed price target raised to $211 from $209 at BofA
- Insmed: Early Brinsupri Momentum but Policy Uncertainty and 2026 Pipeline Catalysts Justify Hold Rating
- Insmed price target lowered to $208 from $234 at Wells Fargo
- Brinsupri’s Breakout Growth, Robust Balance Sheet, and Upcoming Clinical Catalysts Underpin Buy Rating